A 4-year phase II study of everolimus in NF2 patients with growing vestibular schwannomas

被引：0
|
作者：
Stéphane Goutagny
Marco Giovannini
Michel Kalamarides
机构：
[1] Assistance Publique Hôpitaux de Paris,Neurochirurgie
[2] Hôpital Beaujon,undefined
[3] Hôpital Pitié Salpêtrière,undefined
[4] Assistance Publique Hôpitaux de Paris,undefined
[5] University of California Los Angeles,undefined
来源：
Journal of Neuro-Oncology | 2017年 / 133卷
关键词：
Bevacizumab; Meningioma; Everolimus; Rebound Effect; Vestibular Schwannoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：443 / 445
页数：2
相关论文
共 50 条
  • [1] Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas
    Goutagny, Stephane
    Raymond, Eric
    Esposito-Farese, Marina
    Trunet, Stephanie
    Mawrin, Christian
    Bernardeschi, Daniele
    Larroque, Beatrice
    Sterkers, Olivier
    Giovannini, Marco
    Kalamarides, Michel
    JOURNAL OF NEURO-ONCOLOGY, 2015, 122 (02) : 313 - 320
  • [2] Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas
    Stéphane Goutagny
    Eric Raymond
    Marina Esposito-Farese
    Stéphanie Trunet
    Christian Mawrin
    Daniele Bernardeschi
    Béatrice Larroque
    Olivier Sterkers
    Marco Giovannini
    Michel Kalamarides
    Journal of Neuro-Oncology, 2015, 122 : 313 - 320
  • [3] Advances in Targeted Therapy for Neurofibromatosis Type 2 (NF2)-Associated Vestibular Schwannomas
    Cumpston, Evan C.
    Rhodes, Steven D.
    Yates, Charles W.
    CURRENT ONCOLOGY REPORTS, 2023, 25 (05) : 531 - 537
  • [4] Natural history of vestibular schwannomas and hearing loss in NF2 patients
    Peyre, M.
    Bernardeschi, D.
    Sterkers, O.
    Kalamarides, M.
    NEUROCHIRURGIE, 2018, 64 (05) : 342 - 347
  • [5] Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas
    Karajannis, Matthias A.
    Legault, Genevieve
    Hagiwara, Mari
    Giancotti, Filippo G.
    Filatov, Alexander
    Derman, Anna
    Hochman, Tsivia
    Goldberg, Judith D.
    Vega, Emilio
    Wisoff, Jeffrey H.
    Golfinos, John G.
    Merkelson, Amanda
    Roland, J. Thomas
    Allen, Jeffrey C.
    NEURO-ONCOLOGY, 2014, 16 (02) : 292 - 297
  • [6] Rates of loss of heterozygosity and mitotic recombination in NF2 schwannomas, sporadic vestibular schwannomas and schwannomatosis schwannomas
    Hadfield, K. D.
    Smith, M. J.
    Urquhart, J. E.
    Wallace, A. J.
    Bowers, N. L.
    King, A. T.
    Rutherford, S. A.
    Trump, D.
    Newman, W. G.
    Evans, D. G.
    ONCOGENE, 2010, 29 (47) : 6216 - 6221
  • [7] Rates of loss of heterozygosity and mitotic recombination in NF2 schwannomas, sporadic vestibular schwannomas and schwannomatosis schwannomas
    K D Hadfield
    M J Smith
    J E Urquhart
    A J Wallace
    N L Bowers
    A T King
    S A Rutherford
    D Trump
    W G Newman
    D G Evans
    Oncogene, 2010, 29 : 6216 - 6221
  • [8] Multiple Unilateral Vestibular Schwannomas: Segmental NF2 or Sporadic Occurrence?
    Carlson, Matthew L.
    Van Gompel, Jamie J.
    JOURNAL OF NEUROLOGICAL SURGERY REPORTS, 2016, 77 (02) : E106 - E108
  • [9] NF2 Genetic Alterations in Sporadic Vestibular Schwannomas: Clinical Implications
    Lassaletta, Luis
    Torres-Martin, Miguel
    Pena-Granero, Carolina
    Maria Roda, Jose
    Santa-Cruz-Ruiz, Santiago
    Castresana, Javier S.
    Gavilan, Javier
    Rey, Juan A.
    OTOLOGY & NEUROTOLOGY, 2013, 34 (07) : 1355 - 1361
  • [10] Advances in Targeted Therapy for Neurofibromatosis Type 2 (NF2)-Associated Vestibular Schwannomas
    Evan C. Cumpston
    Steven D. Rhodes
    Charles W. Yates
    Current Oncology Reports, 2023, 25 : 531 - 537
12345